A: The Commission's independence rules apply to audits of financial statements required by SEC rules, except for those required by Rule 3-05 and 3-14 of Regulation S-X and Item 310(c) and (e) of Regulation S-B.
1 The Centers for Disease Control and Prevention (CDC) recommends 2 doses of quadrivalent meningococcal conjugate vaccine for adolescents 11 through 18 years of age.  The first dose should be given at 11 or 12 years of age, followed by a booster dose at age 16.
One type of MCV4, Menveo, is licensed for use in people aged 2 to 55. Another version, Menactra, is approved for those 9 months to 55 years old. MPSV4 is the only vaccine licensed for use in people over 55 as well as people 2 to 55. Both vaccines protect against four types of meningococcal disease.In 2015, two serogroup B vaccines were given approval and protect against the other two forms of meningococcal disease.MenB-FHpb or Trumenba was approved for a three dose schedule, while MenB-4C Bexsero is approved for two doses.nother version, Menactra, is approved for those 9 months to 55 years old. MPSV4 is the only vaccine licensed for use in people over 55 as well as people 2 to 55. Both vaccines protect against four types of meningococcal disease.